Clinical Trials on Acute HIV Infection

Total 77764 results

Gilead Sciences
Glaxo Wellcome; Dupont Applied Biosciences

Completed

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

HIV Infections

United States
Gilead Sciences
Bristol-Myers Squibb; Glaxo Wellcome; Dupont Applied Biosciences

Completed

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

HIV Infections

United States
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients

HIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Netherlands, Finland, Ireland, Portugal, Switzerland
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Hepatitis C Infection With HIV Co-Infection

United Kingdom, Germany
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
Gilead Sciences

Completed

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

The Effects of Prednisone on HIV Levels and the Immune System

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

HIV Infections

United States
International Antiviral Therapy Evaluation Center
University Medical Center Groningen; Prothya Biosolutions

Completed

Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

HIV Infections

Netherlands
Glaxo Wellcome

Completed

A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS

HIV Infections

United States
Glaxo Wellcome

Completed

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

HIV Infections

United States, Canada, Argentina, Brazil, Puerto Rico
Anderson Clinical Research
Boehringer Mannheim

Completed

The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients

HIV Infections
Glaxo Wellcome

Completed

A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

HIV Infections

France, Germany
Elizabeth Glaser Pediatric AIDS Foundation
UNITAID

Completed

Evaluating the Feasibility of Point of Care Birth Testing in Eswatini

HIV Infections | HIV/AIDS | Neonatal Infection | Infant Morbidity | Pediatric HIV Infection | Transmission, Perinatal Infection

Swaziland
St. Jude Children's Research Hospital

Active, not recruiting

T-cell Responses to Concurrent HIV and Herpesvirus Infections

HIV Infections | HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients

HIV Infection

United States
Florida International University

Completed

Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings

HIV Infection

Haiti
Ottawa Hospital Research Institute
Pfizer

Completed

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (RIFAMARA)

HIV Infection | HIV-1 Infection | Mycobacterium Avium Complex (MAC)

Canada
University of North Carolina, Chapel Hill
Fogarty International Center of the National Institute of Health

Completed

HIV And Parasitic Infection (HAPI) Study (HAPI)

HIV Coinfection

Malawi
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine (ACTHIVE-001)

HIV-1-infection

Netherlands
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults (M&M)

HIV-1 Infection

United States
Janssen R&D Ireland

Completed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Australia, France, United Kingdom, China, Belgium, Germany, Spain, Argentina, Romania, South Africa, Canada, Denmark, Netherlands, Chile, Puerto Rico, Austria, Russian Federation, Thailand, Sweden, Taiwan
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
Bristol-Myers Squibb

Terminated

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

HIV-1 Infection

Thailand, United States, Australia, Canada, Spain, Colombia, South Africa, Hungary, France, Peru, Argentina, Chile, Mexico
AbbVie (prior sponsor, Abbott)

Completed

Surveillance of Kaletra in Korean Patients

HIV-1 Infection
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Merck Sharp & Dohme LLC

Terminated

MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

HIV-1 Infection
Hospitales Universitarios Virgen del Rocío

Completed

Etravirine Plus 2 Analogs in HIV-infected Patients

HIV-1-infection

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

HIV Infections | HIV Seronegativity

United States
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
National Institute of Allergy and Infectious Diseases...

Recruiting

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multi-Drug Resistant Hiv-1 Infection | HIV-1 Infection

United States
Peking Union Medical College Hospital

Completed

Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection

HIV-infection/AIDS

China
Harvard School of Public Health (HSPH)

Completed

Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)

HIV Infection | Infant Risk for HIV Infection by MTCT
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
Gilead Sciences

Completed

Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine

HIV-1 Infection

South Africa
Imperial College London
Medical Research Council

Terminated

Novel Interventions in HIV-1 Infection (IMIRC1003)

HIV-1 Infection

United Kingdom
Tobira Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

HIV-1 Infection

United States, Puerto Rico
Hospital Clinic of Barcelona

Unknown

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 (DIS-MVC)

HIV-1 Infection

Spain
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
Johns Hopkins University

Completed

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection (Care2Cure)

Hepatitis C, Chronic | HIV

United States
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)

Pre-Exposure Prophylaxis of HIV-1 Infection

United States, Austria, Denmark, United Kingdom, Netherlands, Italy, Germany, Canada, Ireland, France, Spain
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
University of Zurich

Active, not recruiting

BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection: (BELIEVE)

HIV-1-infection

Switzerland
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

HIV-1-infection

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Aelix Therapeutics

Completed

Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)

HIV-1 Infection

Spain
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

HIV-1 Infection

United States
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal

3

Subscribe